MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'billy tauzin'. Sat, 03 Sep 2011 02:38:37 +0100 http://www.medworm.com/index.php?rid=3754077&cid=t_146795_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FctXS71Wdiqk%2F For those spending all their time following the Avandia controversy, you can be forgiven for not realizing that PhRMA named a new ceo yesterday to replace Billy Tauzin. This would be John Castellani, who spent the past nine years as chief executive of the Business Roundtable, the pro-business lobbying group that is chock full of chief executives (see here). He arrives at a precipitous time for the pharmaceutical industry - a collective pipeline thinner than a terribly clogged artery; an historically contentious relationship with Democrats in Congress; a reputation among the public that may rival Toyota (but probably not BP), and a work force that is now devoid of who-knows-how-many scientists, the very type of employee that Lilly ceo John Lechleiter last week wrote this country needs more ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3754077 Wed, 14 Jul 2010 15:47:39 +0100 3754077 http://www.medworm.com/index.php?rid=3750271&cid=t_146795_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fa5bN68miKH4%2F Well, he isn’t a former member of Congress. Instead, the PhRMA board chose a different kind of insider - John Castellani, who spent the past nine years as chief executive of the Business Roundtable, the pro-business lobbying group that is chock full of chief executives. The move comes several months after Billy Tauzin resigned amid bickering over the health care reform deal he orchestrated with the White House. Tauzin, a former Congressman, argued that pursuing a bipartisan approach to the issue - and the Obama administration - was likely to yield more benefits. But that alienated some PhRMA members, many of whom have traditionally backed Republicans (back story). By tapping Castellani, PhRMA gets a known quantity who understands what chief executives want and the power of lobbying.... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3750271 Tue, 13 Jul 2010 14:15:01 +0100 3750271 http://www.medworm.com/index.php?rid=3331285&cid=t_146795_87_f&fid=38368&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FDisruptiveWomenInHealthCare%2F%7E3%2FI7gar2l91uE%2F Help Wanted: PHRMA ISO New CEO By Robin Strongin | February 13th, 2010 Immediately after the snow stopped falling in Washington DC this week, another news story took DC by storm–the resignation of Billy Tauzin, effective June 30th. Mr. Tauzin’s departure comes at a critical time for those involved with health reform efforts, not to mention PHRMA’s own thick portfolio of issues that include patents and trade, the economy, taxes (think offshore), and shrivelling pipelines, just to name a few. The job pays well, but the applicant will surely inherit a daunting to-do list… Read the rest of Robin’s “Help Wanted: PHRMA ISO New CEO” post. Stop Running Red Lights AND Pay for Health Care Reform By Rosemary Gibson | February 1st, 2010 With all the hand wringing about health... Disruptive Women in Health Care blogs http://www.medworm.com/rss/comments.php?id=3331285 Wed, 03 Mar 2010 21:35:08 +0100 3331285 http://www.medworm.com/index.php?rid=3271191&cid=t_146795_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2010%2F02%2Fbilly.html Jim Edwards has more (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=3271191 Sun, 14 Feb 2010 04:10:00 +0100 3271191 http://www.medworm.com/index.php?rid=3267198&cid=t_146795_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fzx_BhmEZ7OA%2F After five years heading the pharmaceutical industry lobbying machine in Washington, DC, Billy Tauzin has resigned from PhRMA amid bickering over his deal with the White House over health care reform. The former Louisiana congressman, a 66-year-old cancer survivor who was paid $2 million a year, will formally leave on June 30 (read the bio). His departure was precipitated by his calculated move that industry would benefit by working with the Obama administration, which alienated some PhRMA members and many Republicans, who have traditionally received industry backing. Under his tutelage, for instance, the trade group increased support for Democrats in an effort to become more of a bipartisan organization. The deal he helped broker had drugmakers contributing $80 billion over a decade to he... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3267198 Fri, 12 Feb 2010 13:51:26 +0100 3267198 http://www.medworm.com/index.php?rid=3178985&cid=t_146795_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FDPiZK0lyD2I%2F What a difference a few years can make. Drugmakers want a provision of the healthcare reform legislation, which offers 12 years of exclusivity, to remain intact because it offers market exclusivity by delaying lower-cost competiton. However, the White House and Henry Waxman, who chairs the House Energy & Commerce Committee, are jockeying to lower that to anywhere from seven to 10 years, the Associated Press writes. And so the industry is threatening to bolt. In an e-mail obtained by the AP, PhRMA told its board members that “we could not support the bill” if the industry is given less than 12 years of competitive protection for the expensive products. “Please activate immediately all of your contacts,” said the e-mail from Billy Tauzin, the group’s presid... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3178985 Sat, 16 Jan 2010 15:37:54 +0100 3178985 http://www.medworm.com/index.php?rid=2326621&cid=t_146795_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F04%2F01%2Fphrma-report-shows-record-number-of-development-drugs-to-treat-cancer-63-ovarian-cancer-203-solid-tumor-drugs-listed%2F “Responding to President Obama’s call for ‘a cure for cancer in our time,’ the Pharmaceutical Research and Manufacturers of America (PhRMA) delivered a new report today on medicines in the research pipeline for cancer. The report shows that America’s pharmaceutical research and biotechnology companies are testing a record 861 new cancer medicines and vaccines. The [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2326621 Wed, 01 Apr 2009 21:06:11 +0100 2326621 http://www.medworm.com/index.php?rid=1914608&cid=t_146795_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F10%2Frope-sale-on-schip-of-fools.html With a liberal supermajority in Washington increasingly possible, business is trying to buy up protection, in the hope that Democrats will go easier on them. Henry Waxman is no doubt grateful for this offer of the rope with which he will hang them.Most notable is the drug industry's $13.2 million ad buy to prop up 28 Congressional candidates, many of them vulnerable and all but three of them Democrats. Funded by the Pharmaceutical Research and Manufacturers of America, the industry trade group, the spots salute politicians who supported last fall's unsuccessful $60 billion expansion of the State Children's Health Insurance Program (Schip). Democrats failed to override President Bush's vetoes, but they'll prevail on their next try -- then continue on their march to national health care.More... PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1914608 Wed, 29 Oct 2008 10:46:00 +0100 1914608 http://www.medworm.com/index.php?rid=1625794&cid=t_146795_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F336339629%2F The ‘cagey Cajun,’ who once chaired the House Energy and Commerce Committee and now heads the PhRMA trade group, says he has been spending some of his time tutoring ostrich-like ceo’s on the fine points of making favorable impressions on an angry Congress. “Your house is on fire, and you’re still smoking in bed,” he says he warned pharma execs in a conference call earlier this year. And so, says Tauzin, the industry is paying for past mistakes. “It’s an accumulation of things some companies did over the years, Now, it’s death by a thousand cuts.” And somehow, “we gotta stop the bleeding.” Unfortunately for Billy’s clients, they have yet to develop a pill that can generate trust. Hat tip to the WSJ Health blog (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1625794 Tue, 15 Jul 2008 18:52:49 +0100 1625794 http://www.medworm.com/index.php?rid=1625598&cid=t_146795_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F07%2Fbilly-barks.html “It’s an accumulation of things some companies did over the years, now it’s death by a thousand cuts.” He told drugmakers, “We gotta stop the bleeding.”Good (ole) boy! (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1625598 Tue, 15 Jul 2008 17:13:00 +0100 1625598 http://www.medworm.com/index.php?rid=865683&cid=t_146795_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F155334039%2F The position by the trade group is revealed in a letter written by Billy Tauzin, PhRMA’s ceo, to Essential Action, one of several advocacy groups that are pushing drugmakers to disclose their global contributions. The reason? Concern that charitable and educational donations result in off-label marketing by groups receiving funds; mask the agendas of public policy groups that debate policy issues, and allow researchers to circumvent normal disclosure requirements. Two months ago, the groups wrote the ceo of each drugmaker and large trade group asking them to commit to full disclosure on a worldwide basis. Since then, Lilly agreed, expanding an earlier promise to reveal all US donations. But the International Federation of Pharmaceutical Manufacturers Associations declined, saying dis... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=865683 Wed, 12 Sep 2007 11:38:34 +0100 865683